|
1
|
Packham MA and Mustard JF: The role of
platelets in the development and complication of atherosclerosis.
Semin Hematol. 23:8–26. 1986.PubMed/NCBI
|
|
2
|
Ruggeri ZM: Mechanisms initiating platelet
thrombus formation. Thromb Haemost. 78:611–616. 1997.PubMed/NCBI
|
|
3
|
Ruggeri ZM: Platelets in atherothrombosis.
Nat Med. 8:1227–1234. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brass LF: Thrombin and platelet
activation. Chest. 124(Suppl 3): 18S–25S. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lindholm LH and Mendis S: Prevention of
cardiovascular disease in developing countries. Lancet.
370:720–722. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Furie B and Furie BC: Mechanisms of
thrombus formation. N Engl J Med. 359:938–949. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gross PL and Weitz JI: New antithrombotic
drugs. Clin Pharmacol Ther. 86:139–146. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Collins B and Hollidge C: Antithrombotic
drug market. Nat Rev Drug Discov. 2:11–12. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gaglia MA Jr, Manoukian SV and Waksman R:
Novel antiplatelet therapy. Am Heart J. 160:595–604. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fong J, Cheng-Ching E, Hussain MS, Katzan
I and Gupta R: Predictors of biochemical aspirin and clopidogrel
resistance in patients with ischemic stroke. J Stroke Cerebrovasc
Dis. 20:227–230. 2011. View Article : Google Scholar
|
|
11
|
Fitzgerald R and Pirmohamed M: Aspirin
resistance: effect of clinical, biochemical and genetic factors.
Pharmacol Ther. 130:213–225. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Barrett NE, Holbrook L, Jones S, et al:
Future innovations in antiplatelet therapies. Br J Pharmacol.
154:918–939. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jackson SP and Schoenwaelder SM:
Antiplatelet therapy: in search of the ‘magic bullet’. Nat Rev Drug
Discov. 2:775–789. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Angiolillo DJ, Fernandez-Ortiz A, Bernardo
E, et al: Variability in individual responsiveness to clopidogrel:
clinical implications, management, and future perspectives. J Am
Coll Cardiol. 49:1505–1516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tsai IL, Lin WY, Teng CM, et al: Coumarins
and antiplatelet constituents from the root bark of Zanthoxylum
schinifolium. Planta Med. 66:618–623. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ballabeni V, Tognolini M, Bertoni S, et
al: Antiplatelet and antithrombotic activities of essential oil
from wild Ocotea quixos (Lam) Kosterm (Lauraceae) calices from
Amazonian Ecuador. Pharmacol Res. 55:23–30. 2007. View Article : Google Scholar
|
|
17
|
Seo EJ, Lee DU, Kwak JH, et al:
Antiplatelet effects of Cyperus rotundus and its component
(+)-nootkatone. J Ethnopharmacol. 135:48–54. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fuentes E and Palomo I: Relationship
between platelet PPARs, cAMP levels, and P-Selectin expression:
Antiplatelet activity of natural products. Evid Based Complement
Alternat Med. 2013:8617862013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fuentes E, Caballero J, Alarcón M, Rojas A
and Palomo I: Chlorogenic acid inhibits human platelet activation
and thrombus formation. PLoS One. 9:e906992014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yoshiaki A, Keita K, Tsutomu H, et al:
Four new hydrolysable tannins and an acylated flavonol glycoside
from Euphorbia maculate. Can J Chem. 75:727–733. 1997. View Article : Google Scholar
|
|
21
|
Cao X, Wang W, Zhou L, Cui X and Song X:
Comparison on mass fraction of total flavonoids and tannin of three
kinds of herba Euphorbiae Humifusae and their antibacaterial
activity in vitro. Acta Agriculturae Boreali-Occidentalis Sinica.
21:184–188. 2012.
|
|
22
|
Kuerbannisha M, Zulipiya T, Gulina D,
Xieraili T and Silafu A: Determination of rutin and quercitrin in
the antifungal extract from Euphorbia maculate. Lishizhen Medicine
and Materia Medica Research. 22:2584–2585. 2011.
|
|
23
|
Liu S, Jiang D and Li L: Research on the
total flavonoids’ content and antioxidant activity of Euphorbia
maculata and Euphorbia humifusae. J Hunan Agr U Nat Sci.
33:287–288. 2007.
|
|
24
|
Lee BK, Lee DH, Park S, et al: Effects of
KR-33028, a novel Na+/H+ exchanger-1
inhibitor, on glutamate-induced neuronal cell death and
ischemia-induced cerebral infarct. Brain Res. 1248:22–30. 2009.
View Article : Google Scholar
|
|
25
|
Ryu KH, Han HY, Lee SY, et al: Ginkgo
biloba extract enhances antiplatelet and antithrombotic effects of
cilostazol without prolongation of bleeding time. Thromb Res.
124:328–334. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mustard JF, Perry DW, Ardlie NG and
Packham MA: Preparation of suspensions of washed platelets from
humans. Br J Haematol. 22:193–204. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee BJ, Jo IY, Bu Y, et al: Antiplatelet
effect of Spatholobus suberectus via inhibition of glycoprotein
IIb/IIIa receptor. J Ethnopharmacol.
134:460–467. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cho J, Furie BC, Coughlin SR and Furie B:
A critical role for extracellular protein disulfide isomerase
during thrombus formation in mice. J Clin Invest. 118:1123–1131.
2008.PubMed/NCBI
|
|
29
|
Majid A, Delanty N and Kantor J:
Antiplatelet agents for secondary prevention of ischemic stroke.
Ann Pharmacother. 35:1241–1247. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wijns W, Kolh P, Danchin N, et al:
Guidelines on myocardial revascularization. Eur Heart J.
31:2501–2555. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Albers GW and Amarenco P: Combination
therapy with clopidogrel and aspirin: can the cure results be
extrapolated to cerebrovascular patients? Stroke. 32:2948–2949.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jin YR, Hwang KA, Cho MR, et al:
Antiplatelet and antithrombotic activities of CP201, a newly
synthesized 1,4-naphthoquinone derivative. Vasc Pharmcol. 41:35–41.
2004. View Article : Google Scholar
|
|
33
|
Kunapuli SP, Dorsam RT, Kim S and Quinton
TM: Platelet purinergic receptors. Curr Opin Pharmacol. 3:175–180.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hollopeter G, Jantzen HM, Vincent D, Li G,
England L and Ramakrishnan V: Identification of the platelet ADP
receptor targeted by antithrombotic drugs. Nature. 409:202–207.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gachet C: P2 receptors, platelet function
and pharmacological implications. Thromb Haemost. 99:466–472.
2008.PubMed/NCBI
|
|
36
|
Cattaneo M: Platelet P2 receptors: old and
new targets for antithrombotic drugs. Expert Rev Cardiovasc Ther.
5:45–55. 2007. View Article : Google Scholar
|
|
37
|
Cattaneo M: New P2Y12 blockers. J Thromb
Haemost. 7(Suppl 1): 262–265. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jakubowski JA, Winters KJ, Naganuma H and
Wallentin L: Prasugrel: a novel thienopyridine antiplatelet agent.
A review of preclinical and clinical studies and the mechanistic
basis for its distinct antiplatelet profile. Cardiovasc Drug Rev.
25:357–374. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Akiyama H, Kudo S and Shimizu T: The
absorption, distribution and excretion of a new antithrombotic and
vasodilating agent, cilostazol, in rat, rabbit, dog and man.
Arzneimittelforschung. 35:1124–1132. 1985.PubMed/NCBI
|
|
40
|
Li Y and Wang N: Antithrombotic effects of
Danggui, Honghua and potential drug interaction with clopidogrel. J
Ethnopharmacol. 128:623–628. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Renné T, Nieswandt B and Gailani D: The
intrinsic pathway of coagulation is essential for thrombus
stability in mice. Blood Cell Mol Dis. 36:148–151. 2006. View Article : Google Scholar
|
|
42
|
Azevedo AP, Farias JC, Costa GC, et al:
Anti-thrombotic effect of chronic oral treatment with Orbignya
phalerata Mart. J Ethnopharmacol. 111:155–159. 2007. View Article : Google Scholar
|
|
43
|
Mann KG: Thrombin: can’t live without it;
probably die from it. Chest. 124(Suppl 3): 1S–3S. 2003. View Article : Google Scholar
|
|
44
|
Jennings LK: Mechanisms of platelet
activation: need for new strategies to protect against
platelet-mediated atherothrombosis. Thromb Haemost. 102:248–257.
2009.PubMed/NCBI
|
|
45
|
Mitchell MD, Bibby JG, Hicks BR, et al:
Thromboxane B2 and human parturition: concentrations in the plasma
and production in vitro. J Endocrinol. 78:435–441. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Storey RF, Judge HM, Wilcox RG and
Heptinstall S: Inhibition of ADP-induced P-selectin expression and
platelet-leukocyte conjugate formation by clopidogrel and the P2Y12
receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost.
88:488–494. 2002.PubMed/NCBI
|
|
47
|
Barton JF, Hardy AR, Poole AW and Mundell
SJ: Reciprocal regulation of platelet responses to P2Y and
thromboxane receptor activation. J Thromb Haemost. 6:534–543. 2008.
View Article : Google Scholar
|
|
48
|
Viinikka L and Ylikorkala O: Measurement
of thromboxane B2 in human plasma or serum by radioimmunoassay.
Prostaglandins. 20:759–766. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Plow EF and Ginsberg MH: Cellular
adhesion: GPIIb/IIIa as a prototypic adhesion receptor. Prog Hemost
Thromb. 9:117–156. 1989.
|
|
50
|
Helft G, Gilard M, Feuvre Le C and Zaman
AG: Drug insight: antithrombotic therapy after percutaneous
coronary intervention in patients with an indication or
anticoagulation. Nat Clin Pract Cardiovasc Med. 3:673–680. 2006.
View Article : Google Scholar : PubMed/NCBI
|
